# Vaxart, Inc. (VXRT) · Edgar & Edgarette company card

> Vaxart (VXRT) grew revenue 727% in FY2025 to $237 million, operating margin 7.6% against a -15.8% median for biological products, (no diagnostic substances), equity 47.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 72444 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VXRT) · [JSON](https://www.pops4.com/boards/company/VXRT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $237M |
| Revenue growth, 1 year | 726.7% |
| Revenue growth per year | 303.8% |
| Operating margin | 7.6% (prior year -231.0%) |
| Net margin | 6.9% |
| Operating cash flow | $8M |
| Capital spending | $145,000 |
| Free cash flow | $8M |
| Cash | $54M |
| Long-term debt | — |
| Total assets | $186M |
| Total equity | $88M |
| Equity ÷ assets | 47.2% |
| Return on equity | 18.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -4.73 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: New ship · no warning signs

## Edgarette's reading

Exposure: revenue $237.3M (FY2025). Experience: revenue up 726.7% on the year, up 303.8% a year over 4 years; operating margin 7.6%, up from -231.0%. Soundness: equity 47.2% of assets, return on equity 18.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.1B and $2.9B next year (method v4.1: its own 1-year record of growth weighed at 0% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.9B to $3.2B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 7.6% against a -15.8% median; growth 726.7% against 21.4%.

Range logged 2026-10-20, receipt 47f84e5327602fc0, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-19 ([filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926032932/0001437749-26-032932-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926035291/0001437749-26-035291-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926035275/0001437749-26-035275-index.htm)
- 8-K · filed 2026-10-19 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926032932/0001437749-26-032932-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926030318/0001437749-26-030318-index.htm)
- 8-K · filed 2026-08-25 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/0001437749-26-028916-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/72444/000143774926026289/0001437749-26-026289-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000072444.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=72444

## Cite

POPS4, Edgar & Edgarette: Vaxart, Inc. (VXRT) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/VXRT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

